Chemotherapy regimen

This page covers all Chemotherapy regimen drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD20, EGFR, CD20 (rituximab).

Targets

CD20 · EGFR · CD20 (rituximab) · thymidylate synthase, DNA repair enzymes · VEGF · VEGF, thymidylate synthase, DNA repair

Phase 3 pipeline (16)

• modified FOLFIRINOX · AbbVie · Oncology
  Modified FOLFIRINOX is a chemotherapy regimen that combines four drugs to target rapidly dividing cancer cells.
• Long Course Adjuvant Chemotherapy · Trans Tasman Radiation Oncology Group · Oncology
  Long course adjuvant chemotherapy delivers extended cycles of cytotoxic chemotherapy after primary cancer treatment to eliminate residual disease and reduce recurrence risk.
• R-mini-CHOP · AstraZeneca · Oncology
  R-mini-CHOP is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone.
• mFOLFOX6 plus cetuximab · West China Hospital · Oncology
  mFOLFOX6 plus cetuximab is a chemotherapy regimen that targets cancer cells by inhibiting DNA synthesis and inducing apoptosis.
• Alternating chemotherapy · PETHEMA Foundation · Oncology
  Alternating chemotherapy uses sequential administration of different chemotherapeutic agents to overcome drug resistance and improve treatment efficacy.
• CHOP21 · University Hospital, Grenoble · Oncology
  CHOP21 is a chemotherapy regimen used to treat various types of cancer.
• TPF+CCRT · Guiyang Medical University · Oncology
  TPF+CCRT is a chemotherapy regimen that combines docetaxel, cisplatin, and fluorouracil to target rapidly dividing cancer cells.
• R-DA-EPOCH-21 + auto-SCT · National Research Center for Hematology, Russia · Oncology
  R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab with the EPOCH chemotherapy regimen, followed by an autologous stem cell transplant.
• Perioperative mFLOT · Sixth Affiliated Hospital, Sun Yat-sen University · Oncology
  Perioperative mFLOT is a chemotherapy regimen used to treat various types of cancer.
• Placebo、CAPOX · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Oncology
  CAPOX is a chemotherapy regimen that combines capecitabine and oxaliplatin to treat cancer.
• VDCLD regimen · Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · Oncology
  The VDCLD regimen is a combination of chemotherapy drugs used to treat various types of cancer.
• VIP/ABVD · University Hospital, Grenoble · Oncology
  VIP/ABVD is a chemotherapy regimen used to treat Hodgkin lymphoma.
• R-mNHL-BFM-90 · National Research Center for Hematology, Russia · Oncology
  R-mNHL-BFM-90 is a chemotherapy regimen used to treat certain types of non-Hodgkin lymphoma.
• R-DA-EPOCH-21 · National Research Center for Hematology, Russia · Oncology
  R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab, doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone.
• Standard CHOP · Japan Clinical Oncology Group · Oncology
  Standard CHOP is a chemotherapy regimen that combines cyclophosphamide, doxorubicin, vincristine, and prednisone to target rapidly dividing cancer cells.
• mFOLFOX6-bevacizumab · GERCOR - Multidisciplinary Oncology Cooperative Group · Oncology
  mFOLFOX6-bevacizumab is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin with bevacizumab, an anti-angiogenic monoclonal antibody.

Phase 2 pipeline (9)

• FEC75 · GlaxoSmithKline · Oncology
  FEC75 is a chemotherapy regimen that combines 5-fluorouracil, epirubicin, and cyclophosphamide to treat breast cancer.
• Abb-R-CHOP · Asan Medical Center · Oncology
  Abb-R-CHOP is a combination chemotherapy regimen that targets rapidly dividing cancer cells.
• FOLFIRI.3 · Federation Francophone de Cancerologie Digestive · Oncology
  FOLFIRI is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, irinotecan, and folinic acid to target rapidly dividing cancer cells.
• Folfox plus Bevacizumab and reolysin · Canadian Cancer Trials Group · Oncology
  Folfox plus Bevacizumab and reolysin is a combination chemotherapy regimen that targets rapidly dividing cancer cells and inhibits angiogenesis.
• FOLFIRINOX treatment · Centre Georges Francois Leclerc · Oncology
  FOLFIRINOX is a chemotherapy regimen that combines four different drugs to target rapidly dividing cancer cells.
• CEEP regimen · French Innovative Leukemia Organisation · Oncology
  CEEP regimen is a combination of chemotherapy drugs used to treat acute lymphoblastic leukemia.
• CHOP-R · CTI BioPharma · Oncology
  CHOP-R is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone.
• FOLFIFINOX · AIO-Studien-gGmbH · Oncology
  FOLFIRINOX is a chemotherapy regimen that combines four different drugs to target rapidly dividing cancer cells.
• CONVENTIONAL ABVD · Ospedale Santa Croce-Carle Cuneo · Oncology
  This chemotherapy regimen combines Adriamycin, Bleomycin, Vinblastine, and Dacarbazine to target rapidly dividing cancer cells.